Market capitalization | $33.33m |
Enterprise Value | $45.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.89 |
P/S ratio (TTM) P/S ratio | 1.40 |
P/B ratio (TTM) P/B ratio | 1.25 |
Revenue growth (TTM) Revenue growth | 46.37% |
Revenue (TTM) Revenue | $23.84m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 24 24 |
46%
46%
|
|
Gross Profit | 6.37 6.37 |
97%
97%
|
|
EBITDA | -0.57 -0.57 |
85%
85%
|
EBIT (Operating Income) EBIT | -3.26 -3.26 |
49%
49%
|
Net Profit | -3.81 -3.81 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.
Head office | United States |
CEO | Michael Brigham |
Employees | 79 |
Founded | 1982 |
Website | www.immucell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.